[Recurrent facial herpes simplex. Treatment with active paramunization].
132 patients with herpes simplex manifestations were treated with PIND, a heterologous pox-virus-antigen, that stimulates T-cells and macrophages. The shortening of duration of the disease, the subsequent relief from pain and the decrease in frequency of recurrence was proven.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000276:immunology*; D002648:Child; D005148:Facial Dermatoses / Q000276:immunology / Q000628:therapy*; D005260:Female; D006561:Herpes Simplex / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012901:Variola virus / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral
Herpes simplex recidivans im Gesichtsbereich. Die Behandlung durch aktive Paramunisierung.